RGNX NAAVIGATE Doses First Patient: $100M AbbVie Milestone

REGENXBIO (RGNX) dosed the first patient in the Phase IIb/III NAAVIGATE trial of surabgene lomparvovec (sura-vec, ABBV-RGX-314), a one-time gene therapy for diabetic retinopathy delivered via suprachoroidal injection. The milestone triggers a $100 million payment from AbbVie.

RGNX closed at $9.73 on July 24. The stock has been under pressure as the gene therapy sector de-rated, but the AbbVie milestone plus registrational entry in diabetic retinopathy marks a de-risking event.

What NAAVIGATE is testing

NAAVIGATE is a multicenter, randomized, masked, sham-controlled Phase IIb/III trial enrolling patients with nonproliferative diabetic retinopathy (NPDR) without center-involved diabetic macular edema. The Phase IIb portion will enroll approximately 135 participants in the United States. Patients receive sura-vec at 1.0x10^12 genome copies per eye, the dose level evaluated as dose level 3 in the ALTITUDE Phase II trial, along with short-course topical prophylactic steroids.

The primary endpoint is a greater than 2-step improvement on the Diabetic Retinopathy Severity Scale (DRSS) at one year, a clinically meaningful reduction in retinopathy severity the FDA has used in prior approvals including Regeneron’s Eylea.

The mechanism and why delivery matters

Sura-vec uses a NAV AAV8 vector to deliver a gene encoding an anti-VEGF antibody fragment directly into retinal tissue, enabling the eye to produce its own sustained VEGF inhibition after a single administration. Current anti-VEGF treatments for diabetic retinopathy, including Regeneron’s Eylea (aflibercept), Roche’s Lucentis (ranibizumab), and Roche’s Vabysmo (faricimab), require intravitreal injections every 4 to 12 weeks. A one-time gene therapy would eliminate that treatment burden.

The delivery route is the differentiator. Sura-vec in NAAVIGATE is delivered suprachoroidally, placing the vector between the choroid and sclera without entering the vitreous cavity. This in-office approach offers advantages in biodistribution and procedure tolerability relative to intravitreal or subretinal delivery, which requires surgery.

The $100M AbbVie milestone and the partnership

AbbVie partnered with REGENXBIO on the RGX-314 program in a 2021 deal worth up to $1.6 billion in milestones. The $100 million payment for first patient dosed in NAAVIGATE adds to REGENXBIO’s cash runway. A second $100 million is tied to first patient dosing in a subsequent Phase III trial. The diabetic retinopathy indication affects nearly 10 million Americans and is the leading cause of vision loss in working-age adults.

Prior data

The ALTITUDE Phase II trial evaluated sura-vec in diabetic retinopathy at three dose levels. Two-year data showed durable efficacy at dose level 3 with no intraocular inflammation in 15 patients, supporting the move into the registrational NAAVIGATE trial.

Sura-vec is also under investigation for wet AMD via subretinal delivery in the ATMOSPHERE and ASCENT trials, with topline data expected in Q4 2026. For context on the wet AMD anti-VEGF market, see our coverage of Lytenava’s FDA approval in wet AMD.

Risks

Gene therapy in ophthalmology has a mixed track record. Spark Therapeutics’ Luxturna, approved in 2017 for an inherited retinal dystrophy, remains the only FDA-approved ocular gene therapy with under $50 million in annual revenue due to the ultra-rare population and complex surgical delivery. Sura-vec targets a much larger population but must prove suprachoroidal delivery achieves consistent transduction.

The Q4 2026 wet AMD readouts from ATMOSPHERE and ASCENT are the other binary catalysts. REGENXBIO’s reliance on AbbVie for development funding is both a strength and a risk: AbbVie controls the commercial trajectory.

What to watch next

The Q4 2026 topline data from the ATMOSPHERE and ASCENT wet AMD trials. Those readouts will determine whether sura-vec works across retinal disease or only in diabetic retinopathy. The NAAVIGATE primary endpoint readout at one year is further out.

REGENXBIO press release via PR Newswire | CGTLive coverage